Sravan Emany

I've been pulling on a wire, but it just won't break / Love Philadelphia sports and FFC /@johnshopkins, @jhutennis, and @saishopkins alumnus

[Sravan Emany @semany]

@CottageTactico Totally unclear. That’s the hope we can cling to. And maybe this won’t prove out positively for us in 2026/7. It may take time to get the right players to have success. The worst fear is that the ambition is to audition young talent in a high end system just to profit from them

[Sravan Emany @semany]

@CottageTactico I’m as excited as any #FFC supporter about this project. At the same time, how many times have we seen a successful “system” implemented at a club and have success without the right talent? How many + examples can you name? I guess that’s why we’re so focused on who they bring in

[Beam Therapeutics @BeamTx]

We're honored to share that Beam has been named a TIME100 Most Influential Company! @TIME recognized 100 companies charting an essential path forward & we're thrilled to have our work celebrated as we strive to break new ground to support patients suffering from serious diseases.

[Rich Hofmann @rich_hofmann]

Rob Thomson is a good man who had a good run as Phillies manager.

This is the most bummed I have been about a manager change since Charlie Manuel left with the Wawa bag. Since Charlie, Topper had the best run here.

[Beam Therapeutics @BeamTx]

Today, Beam announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency (AATD) and the selection of 60 mg as the optimal biological dose to advance into pivotal development to support potential accelerated approval.

[John Evans @john_evans3]

Excited to share our updated BEAM-302 data!

This is now a robust, industry-leading data set with over 29 total patients treated.

https://t.co/THwIsfxvQG

[Kyverna Therapeutics @Kyverna_Tx]

We are pleased to welcome Sravan K. Emany and Andrew Miller, PhD, to our Board of Directors. Their expertise and leadership in #biotech will be instrumental as we advance towards commercialization. Read more here: https://t.co/XXvvftivUk

[Beam Therapeutics @BeamTx]

Today, Beam announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease.

[John Evans @john_evans3]

Second, we have closed a strategic financing with Sixth Street for up to $500M of non-dilutive capital, underwriting the launch of risto-cel in sickle cell disease and allowing us to continue investing in the growth of our pipeline:
https://t.co/GeS8RUmcWA

[John Evans @john_evans3]

Highlights:

FDA alignment on potential accelerated approval pathway for BEAM-302 in AATD

BEAM-302 new data by end of Q1

BEAM-301 data this year

Next liver program 1H26

Risto-cel SCD BLA filing as early as end 2026

In vivo LNP for next wave SCD

1.25B cash, runway into 2029

[John Evans @john_evans3]

Excited to share Beam's 2026 update and strategic priorities:

https://t.co/RlxAMH0ZVz

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Super excited about this amazing deal based on transformative science!

As a founder and Chair, this was one fun ride!

Congrats to Rob, Giles, and the entire Orbital team!!!

[John Evans @john_evans3]

Congratulations to co-founders Pino Ciaramella @gciaramella1 and John Maraganore @JMaraganore, all members of the Beam team who contributed, our investors, and the entire Orbital team who have done amazing work advancing this science and creating an exciting new pipeline!

[John Evans @john_evans3]

Excited to see this transformative acquisition of Orbital by BMS for $1.5B, which speaks to the incredible potential of the company's platform. BMS’s strong leadership position in immunology and cell therapy will help accelerate this science to patients.

https://t.co/qxJiKXBwAL

[Riley Kennedy @RileyKennedy25]

Mira Emany, Kent Place School (N.J.), Steps NJ, is headed to Dartmouth‼️

@DartmouthWLax lands their 2nd Recruit in the Class of 2027💥💫

[Sravan Emany @semany]

@quimby_kevin Congratulations!

[ILWomen @ILWomen]

Lacrosse Masters headed to New port in July for some high-focus training with college coaches as the summer recruiting window wound down.

Caldwell, Emany, Oliven Lead ILWomen's 2⃣0⃣ Standouts at 2025 Lacrosse Masters Newport
https://t.co/besNJfbiiI

[Alex & Books 📚 @AlexAndBooks_]

There should be no tax on books.

[John Evans @john_evans3]

Beautiful story here about a customized base editing treatment for a newborn baby with a life threatening genetic disease.

Congratulations to @kiranmusunuru, Rebecca Ahrens-Nicklas, @UrnovFyodor, and the rest of the team that made this happen.

[John Evans @john_evans3]

Privileged to share initial data for BEAM-302 today in alpha-1 antitrypsin deficiency (AATD)!

AATD is a severe, progressive disease impacting both lung and liver function that affects 100,000 people in the US

https://t.co/wZcQvAblR0